The CBR3 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the human Raji B lymphoblastoid cell line. This product offers targeted disruption of the CBR3 gene, creating a loss-of-function model for investigating carbonyl reductase biology in lymphoid cells. The polyclonal format ensures a heterogeneous pool of edited cells, minimizing clonal artifacts and enabling population-level functional assays.
Raji is an EBV-positive B lymphoblastoid line originally established from a Burkitt’s lymphoma patient. These cells display surface immunoglobulin expression and robust proliferation, making them a classic model for humoral immunity, B-cell malignancies, and drug development. Their EBV-driven background also facilitates studies on viral-host interactions in lymphomagenesis.
CBR3 encodes an NADPH-dependent carbonyl reductase that catalyzes the reduction of quinones, prostaglandins, and xenobiotics, playing a critical role in detoxification and redox homeostasis. This enzyme is crucial for protecting cells from cytotoxic carbonyl compounds and for the metabolism of endogenous signaling molecules. Its expression is upregulated by stress-responsive transcription factors NFE2L2 (Nrf2) and AhR, and is modulated by PI3K/Akt signaling. CBR3 interacts with NADPH and prostaglandin E2, and cooperates with GSTP1 in phase II metabolism. It functions within pathways including arachidonic acid metabolism, prostaglandin synthesis, and oxidative stress response, with representative components such as KEAP1, PTGS2, HPGD, and the AKR1C family. Gene knockout impairs the reduction of reactive carbonyl species, leading to dysregulated prostaglandin metabolism and elevated reactive oxygen species, thereby disrupting cellular redox balance and affecting downstream survival and proliferation signaling networks.
In Raji cells, CBR3 disruption allows investigation of redox-dependent signaling in the context of B-cell lymphoma and humoral immunity. The polyclonal format captures population-level heterogeneity, making it valuable for studying chemoresistance, viral-host interactions, and metabolic reprogramming without clonal selection bias. This model is particularly advantageous for assessing heterogeneous drug responses and for dissecting the role of CBR3 in lymphocyte biology.
This polyclonal knockout model supports diverse experimental approaches, including western blotting, RT-qPCR, flow cytometry, ROS detection, drug sensitivity and chemosensitivity screening, prostaglandin E2 ELISA, and NADPH/NADP+ ratio measurement. It is well-suited for studies in cancer biology, drug resistance mechanisms, redox biology, immunometabolism, and chemotherapeutic efficacy. Additionally, the cells can be used for co-culture experiments, signaling pathway analysis, and high-throughput chemical screens. For further technical details, please contact Ascent Research.
